Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.21
DGX's Cash to Debt is ranked lower than
52% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. DGX: 0.21 )
DGX' s 10-Year Cash to Debt Range
Min: 0.02   Max: N/A
Current: 0.21

Equity to Asset 0.40
DGX's Equity to Asset is ranked higher than
57% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. DGX: 0.40 )
DGX' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.62
Current: 0.4

0.3
0.62
Interest Coverage 5.89
DGX's Interest Coverage is ranked higher than
52% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 261.43 vs. DGX: 5.89 )
DGX' s 10-Year Interest Coverage Range
Min: 1.82   Max: 17.57
Current: 5.89

1.82
17.57
F-Score: 5
Z-Score: 2.78
M-Score: -2.69
WACC vs ROIC
2.72%
8.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.32
DGX's Operating margin (%) is ranked higher than
91% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. DGX: 13.32 )
DGX' s 10-Year Operating margin (%) Range
Min: -37.2   Max: 20.64
Current: 13.32

-37.2
20.64
Net-margin (%) 6.81
DGX's Net-margin (%) is ranked higher than
86% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. DGX: 6.81 )
DGX' s 10-Year Net-margin (%) Range
Min: -38.73   Max: 11.88
Current: 6.81

-38.73
11.88
ROE (%) 12.33
DGX's ROE (%) is ranked higher than
88% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. DGX: 12.33 )
DGX' s 10-Year ROE (%) Range
Min: -4.13   Max: 21.63
Current: 12.33

-4.13
21.63
ROA (%) 5.17
DGX's ROA (%) is ranked higher than
85% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. DGX: 5.17 )
DGX' s 10-Year ROA (%) Range
Min: -1.6   Max: 11.74
Current: 5.17

-1.6
11.74
ROC (Joel Greenblatt) (%) 82.67
DGX's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 300 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. DGX: 82.67 )
DGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 24.96   Max: 142.93
Current: 82.67

24.96
142.93
Revenue Growth (3Y)(%) 3.60
DGX's Revenue Growth (3Y)(%) is ranked higher than
69% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. DGX: 3.60 )
DGX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 15.4
Current: 3.6

0
15.4
EBITDA Growth (3Y)(%) 4.10
DGX's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. DGX: 4.10 )
DGX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 44.5
Current: 4.1

0
44.5
EPS Growth (3Y)(%) 9.90
DGX's EPS Growth (3Y)(%) is ranked higher than
82% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. DGX: 9.90 )
DGX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 62.3
Current: 9.9

0
62.3
» DGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DGX Guru Trades in Q2 2014

Scott Black 220 sh (New)
Chris Davis 4,672,681 sh (+4465.97%)
Louis Moore Bacon 14,460 sh (+85.38%)
John Rogers 352,928 sh (+19.57%)
HOTCHKIS & WILEY 2,523,400 sh (+1.12%)
Manning & Napier Advisors, Inc 193,424 sh (+1.01%)
Bernard Horn 61,733 sh (unchged)
Steven Cohen 155,400 sh (unchged)
Brian Rogers 3,000,000 sh (unchged)
Jeremy Grantham Sold Out
Larry Robbins Sold Out
Chuck Royce 187,500 sh (-0.58%)
Jeff Auxier 79,000 sh (-1.68%)
Murray Stahl 7,050 sh (-10.19%)
Robert Olstein 82,000 sh (-18.00%)
David Dreman 35,982 sh (-26.19%)
Diamond Hill Capital 124,800 sh (-50.80%)
Richard Pzena 431,100 sh (-55.66%)
Ray Dalio 13,545 sh (-82.85%)
Joel Greenblatt 4,384 sh (-94.26%)
Paul Tudor Jones 8,400 sh (-97.93%)
» More
Q3 2014

DGX Guru Trades in Q3 2014

Joel Greenblatt 238,057 sh (+5330.13%)
Ray Dalio 15,626 sh (+15.36%)
Chuck Royce 213,000 sh (+13.60%)
Murray Stahl 7,750 sh (+9.93%)
Chris Davis 4,879,416 sh (+4.42%)
Manning & Napier Advisors, Inc 195,674 sh (+1.16%)
Brian Rogers 3,000,000 sh (unchged)
Robert Olstein 82,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Diamond Hill Capital Sold Out
Scott Black Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jeff Auxier 78,950 sh (-0.06%)
Richard Pzena 429,700 sh (-0.32%)
John Rogers 348,910 sh (-1.14%)
David Dreman 33,898 sh (-5.79%)
HOTCHKIS & WILEY 1,593,262 sh (-36.86%)
» More
Q4 2014

DGX Guru Trades in Q4 2014

Paul Tudor Jones 9,600 sh (New)
John Hussman 200,000 sh (New)
Jim Simons 850,700 sh (New)
Charles Brandes 186,113 sh (New)
Ray Dalio 53,126 sh (+239.98%)
Chuck Royce 276,800 sh (+29.95%)
John Rogers 386,508 sh (+10.78%)
Chris Davis 5,155,683 sh (+5.66%)
Manning & Napier Advisors, Inc 195,674 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Brian Rogers 3,000,000 sh (unchged)
Richard Pzena Sold Out
Murray Stahl 7,650 sh (-1.29%)
David Dreman 32,431 sh (-4.33%)
Jeff Auxier 74,800 sh (-5.26%)
Robert Olstein 59,000 sh (-28.05%)
HOTCHKIS & WILEY 983,900 sh (-38.25%)
Joel Greenblatt 88,219 sh (-62.94%)
» More
Q1 2015

DGX Guru Trades in Q1 2015

Pioneer Investments 562,413 sh (New)
Ray Dalio 148,088 sh (+178.75%)
Paul Tudor Jones 14,444 sh (+50.46%)
John Rogers 515,958 sh (+33.49%)
John Hussman 220,000 sh (+10.00%)
Bernard Horn 61,733 sh (unchged)
Manning & Napier Advisors, Inc 195,674 sh (unchged)
HOTCHKIS & WILEY Sold Out
Robert Olstein Sold Out
Chris Davis 5,068,925 sh (-1.68%)
Murray Stahl 7,500 sh (-1.96%)
Charles Brandes 174,714 sh (-6.12%)
Jim Simons 584,100 sh (-31.34%)
David Dreman 21,554 sh (-33.54%)
Joel Greenblatt 56,784 sh (-35.63%)
Brian Rogers 1,750,000 sh (-41.67%)
Chuck Royce 117,000 sh (-57.73%)
Jeff Auxier 23,233 sh (-68.94%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Quest Diagnostics Inc

Bernard Horn Comments on Quest Diagnostics - Aug 07, 2014

The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Quest Diagnostics - Mar 05, 2014

Medical diagnostic testing provider Quest Diagnostics, Inc. (DGX) underperformed due to weakness in both volumes and pricing.



From Diamond Hill Capital (Trades, Portfolio)'s Fourth Quarter 2013 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Quest Diagnostics Inc

Charles Brandes' Top Buys During Q4
Charles Brandes (Trades, Portfolio) founded Brandes Investment Partners in 1974, which manages a variety of global equity and fixed-income assets for investors worldwide. Read more...
A Look at John Hussman's Recent Additions to His Portfolio
John Hussman (Trades, Portfolio) of Hussman Strategic Advisors, Inc. is known for not holding back on sharing his opinions about the government's handling of the nation's financial state. He has openly criticized the U.S. Treasury and the Federal Reserve. He is also known for predicting the U.S. Recession in 2008-2009 and since the end of 2009, he has been calling for another financial crisis to come along due to the poor policy choices made by the government. Read more...
DGX: A Healthy Diagnosis
How much are you paying for the revenue of companies in your portfolio? The less you pay per dollar of revenue, the better. Why? Because revenue translates into earning power, and as we know, when earnings grow, they pull up stock prices. As with almost any asset, buying for less is best if it's an investment of some kind. Read more...
The Top Five Guru-Held Mid-Cap Stocks of Q2
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...
Bernard Horn Comments on Quest Diagnostics
The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.60
DGX's P/E(ttm) is ranked higher than
96% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 22.60 )
DGX' s 10-Year P/E(ttm) Range
Min: 9.14   Max: 31.21
Current: 22.6

9.14
31.21
Forward P/E 15.77
DGX's Forward P/E is ranked higher than
96% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 15.77 )
N/A
PE(NRI) 21.00
DGX's PE(NRI) is ranked higher than
96% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 21.00 )
DGX' s 10-Year PE(NRI) Range
Min: 9.53   Max: 22.34
Current: 21

9.53
22.34
P/B 2.60
DGX's P/B is ranked higher than
81% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. DGX: 2.60 )
DGX' s 10-Year P/B Range
Min: 1.85   Max: 4.43
Current: 2.6

1.85
4.43
P/S 1.54
DGX's P/S is ranked higher than
88% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. DGX: 1.54 )
DGX' s 10-Year P/S Range
Min: 1.03   Max: 2.24
Current: 1.54

1.03
2.24
PFCF 19.00
DGX's PFCF is ranked higher than
94% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 19.00 )
DGX' s 10-Year PFCF Range
Min: 8.22   Max: 21.5
Current: 19

8.22
21.5
POCF 11.71
DGX's POCF is ranked higher than
94% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 11.71 )
DGX' s 10-Year POCF Range
Min: 6.98   Max: 14.43
Current: 11.71

6.98
14.43
EV-to-EBIT 14.19
DGX's EV-to-EBIT is ranked higher than
94% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 14.19 )
DGX' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 14.9
Current: 14.19

7.3
14.9
PEG 5.83
DGX's PEG is ranked higher than
92% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 5.83 )
DGX' s 10-Year PEG Range
Min: 0.58   Max: 4.42
Current: 5.83

0.58
4.42
Shiller P/E 19.70
DGX's Shiller P/E is ranked higher than
98% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 19.70 )
DGX' s 10-Year Shiller P/E Range
Min: 12.83   Max: 40.64
Current: 19.7

12.83
40.64
Current Ratio 1.14
DGX's Current Ratio is ranked higher than
50% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. DGX: 1.14 )
DGX' s 10-Year Current Ratio Range
Min: 0.74   Max: 2.15
Current: 1.14

0.74
2.15
Quick Ratio 1.09
DGX's Quick Ratio is ranked higher than
52% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. DGX: 1.09 )
DGX' s 10-Year Quick Ratio Range
Min: 0.7   Max: 2.03
Current: 1.09

0.7
2.03
Days Inventory 8.31
DGX's Days Inventory is ranked higher than
96% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. DGX: 8.31 )
DGX' s 10-Year Days Inventory Range
Min: 6.93   Max: 13.81
Current: 8.31

6.93
13.81
Days Sales Outstanding 46.01
DGX's Days Sales Outstanding is ranked higher than
88% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.63 vs. DGX: 46.01 )
DGX' s 10-Year Days Sales Outstanding Range
Min: 40.51   Max: 89.26
Current: 46.01

40.51
89.26

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.72
DGX's Dividend Yield is ranked higher than
77% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. DGX: 1.72 )
DGX' s 10-Year Dividend Yield Range
Min: 0.58   Max: 2.36
Current: 1.72

0.58
2.36
Dividend Payout 0.39
DGX's Dividend Payout is ranked higher than
91% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 0.39 )
DGX' s 10-Year Dividend Payout Range
Min: 0.09   Max: 0.91
Current: 0.39

0.09
0.91
Dividend growth (3y) 28.20
DGX's Dividend growth (3y) is ranked higher than
92% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.70 vs. DGX: 28.20 )
DGX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 55.4
Current: 28.2

0
55.4
Yield on cost (5-Year) 6.14
DGX's Yield on cost (5-Year) is ranked higher than
91% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. DGX: 6.14 )
DGX' s 10-Year Yield on cost (5-Year) Range
Min: 1.98   Max: 8.05
Current: 6.14

1.98
8.05
Share Buyback Rate 3.30
DGX's Share Buyback Rate is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.20 vs. DGX: 3.30 )
DGX' s 10-Year Share Buyback Rate Range
Min: 0   Max: -17.7
Current: 3.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.10
DGX's Price/DCF (Projected) is ranked higher than
97% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 1.10 )
DGX' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 4.46
Current: 1.1

0.65
4.46
Price/Median PS Value 1.10
DGX's Price/Median PS Value is ranked higher than
80% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. DGX: 1.10 )
DGX' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.62
Current: 1.1

0.23
1.62
Price/Peter Lynch Fair Value 4.50
DGX's Price/Peter Lynch Fair Value is ranked higher than
92% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DGX: 4.50 )
DGX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62   Max: 4.33
Current: 4.5

0.62
4.33
Earnings Yield (Greenblatt) 6.40
DGX's Earnings Yield (Greenblatt) is ranked higher than
94% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. DGX: 6.40 )
DGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.4   Max: 13.7
Current: 6.4

6.4
13.7
Forward Rate of Return (Yacktman) 11.17
DGX's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. DGX: 11.17 )
DGX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 10.9   Max: 33.6
Current: 11.17

10.9
33.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, LIFE, ENZ, IDXX » details
Traded in other countries:QDI.Germany,
Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing. The Company operations are organized in two business groups; Diagnostics Information Services and Diagnostic Solutions group. The Diagnostics Information Services business is a provider of diagnostic information services, which includes providing clinical testing services such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing, as well as related services and insights. The Company offers patients, physicians, hospitals, IDNs, health plans, employers and others the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, Company-owned patient service centers and phlebotomists in physician offices. It provides interpretive consultation through the medical and scientific staff in the industry, including over 725 M.D.s and Ph.D.s, located in the United States, many of whom are recognized leaders in their fields, and genetic counselors. Diagnostic Solutions group offers solutions for insurers, healthcare providers and others. The Company is a provider of risk assessment services for the life insurance industry. The Company is a provider of testing for clinical trials. In addition, it offers healthcare organizations and clinicians robust information technology solutions and diagnostic products, including test kits. The Company is subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which it conducts business.
» More Articles for DGX

Headlines

Articles On GuruFocus.com
Vermillion (VRML) Ovarian Cancer Test Mega-deal; Papa Murphy's Holdings (FRSH) and Wix (WIX) Strong Mar 18 2015 
Charles Brandes' Top Buys During Q4 Feb 11 2015 
A Look at John Hussman's Recent Additions to His Portfolio Feb 06 2015 
DGX: A Healthy Diagnosis Oct 08 2014 
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
Bernard Horn Comments on Quest Diagnostics Aug 07 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S May 28 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/S May 13 2014 

More From Other Websites
Quest Diagnostics (DGX) Stock Higher After Takeover Tweet Caused Spike May 22 2015
Quest chatter triggers huge profits May 22 2015
Kunkle of OptionsHawk Says Quest Tweet Reflected Rumor May 22 2015
Healthcare Providers ETF Calm After Quest Diagnostics Rumor May 22 2015
Quest Diagnostics Spikes to Record on Tweeted M&A Speculation May 22 2015
QUEST DIAGNOSTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 18 2015
Quest Diagnostics Declares Quarterly Cash Dividend May 15 2015
Quest Diagnostics Declares Quarterly Cash Dividend May 15 2015
Quest Diagnostics' QNatal Advanced for Prenatal Screening - Analyst Blog May 14 2015
UMass Memorial seeks stake in Quest Diagnostics subsidiary May 13 2015
Unicorns that earn billions by making real things May 13 2015
Quest Diagnostics to Enhance Quality of Noninvasive Prenatal Screening with QNatal Advanced™ May 12 2015
Quest Diagnostics to Enhance Quality of Noninvasive Prenatal Screening with QNatal Advanced™ May 12 2015
Making Money With Charles Payne: 05/8/15 May 08 2015
The Zacks Analyst Blog Highlights: Celgene, Laboratory Corp. of America Holdings, Quest Diagnostics... May 06 2015
Quest Diagnostics Announces LeukoVantage™, Advancing Precision Medicine for Hematologic... May 04 2015
Quest Diagnostics Announces LeukoVantage™, Advancing Precision Medicine for Hematologic... May 04 2015
Sarissa Capital's biotech bets May 04 2015
10-Q for Quest Diagnostics, Inc. May 03 2015
QUEST DIAGNOSTICS INC Files SEC form 10-Q, Quarterly Report Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK